CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $252.69M, lower than 95% of all stocks globally
- PositionCurrent ratio is 24.26×, higher than 95% of its Biotechnology peers (median 5.71×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
252.69MUSDvs all stocks (USD)
Revenue (TTM)
500.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.55xvs all stocks
52-Week Change
57.61%vs all stocks
Market Capitalization
252.69MUSDvs all stocks (USD)
Enterprise Value
127.52MUSDvs all stocks (USD)
Forward P/E
-5.18xvs Biotechnology peers
Price to Book (MRQ)
2.07xvs Biotechnology peers
Enterprise to Revenue
255.04xvs Biotechnology peers
Enterprise to EBITDA
-3.61xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-2339.60%vs Biotechnology peers
Return on Assets (TTM)
-32.98%vs Biotechnology peers
Return on Equity (TTM)
-51.37%vs Biotechnology peers
Revenue (TTM)
500.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0030USDUpdated Sep 28, 2026Gross Profit (TTM)
500.00KUSDvs all stocks (USD)
EBITDA (TTM)
-35.35MUSDvs all stocks (USD)
Net Income (TTM)
-31.94MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-18.19MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-8.65MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-18.06MUSDvs all stocks (USD)
Pre-tax Income
-16.78MUSDFY2025 · Dec 31, 2025Net Income
-16.78MUSDFY2025 · Dec 31, 2025EBIT
-16.77MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-16.77MUSDFY2025 · Dec 31, 2025Research & Development
10.19MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
7.86MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
10.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3000USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3000USDFY2025 · Dec 31, 2025Basic Shares Outstanding
55.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
55.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-16.78MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-12.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
133.44MUSDFY2025 · Dec 31, 2025Interest Paid
10.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-16.78MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.96MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-87.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
624.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-90.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-320.00KUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-320.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.11MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
126.47MUSDFY2025 · Dec 31, 2025Shares Outstanding
173.80MSharesUpdated Sep 28, 2026Float Shares
138.85MSharesUpdated Sep 28, 2026Shares Short
30.27MSharesUpdated Sep 28, 2026Short Ratio
15.88daysvs all stocks
Short % of Shares Outstanding
17.37%vs all stocks
% Held by Insiders
2.15%vs all stocks
% Held by Institutions
101.13%vs all stocks
Total Cash (MRQ)
125.17MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7180USDUpdated Sep 28, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
24.26xvs Biotechnology peers
Book Value per Share (MRQ)
0.7010USDUpdated Sep 28, 2026Total Assets
134.34MUSDvs all stocks (USD)
Total Current Assets
134.22MUSDFY2025 · Dec 31, 2025Total Liabilities
4.96MUSDFY2025 · Dec 31, 2025Total Non-current Assets
123.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
328.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
4.64MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
133.38MUSDFY2025 · Dec 31, 2025Accounts Payable
930.00KUSDFY2025 · Dec 31, 2025Short-term Debt
71.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
313.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
266.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.59MUSDFY2025 · Dec 31, 2025Retained Earnings
-152.72MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
129.38MUSDvs all stocks (USD)
52-Week Low
0.8100USDUpdated Sep 28, 202652-Week High
2.86USDUpdated Sep 28, 202652-Week Change
57.61%vs all stocks
Beta
1.55xvs all stocks
50-Day MA
1.98USDUpdated Sep 28, 2026200-Day MA
1.93USDUpdated Sep 28, 2026Avg 10-Day Volume
4.75MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.76MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.6500USDUpdated Sep 28, 2026Other Income / Expense
1.28MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 24.26×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 24.26Industry median: 5.71Industry P95: 22.21Peers compared: 260
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $252.69M, lower than 95% of all stocks globallySignificant
Market cap (USD): 252,692,309Global P5: 275,556,405.438
Revenue is $500,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 500,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Lingda Group Co., Ltd.
2 interpretationsLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Xinjiang Machinery Research Institute Co., Ltd.
2 interpretationsLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets